Reckitt Benckiser Plc (RB) in Consumer Health

Company Profile

About This Report

Jul 2018

Though Reckitt Benckiser Plc (RB) has a long history of leadership in the home care industry, the company restructured in early 2018 by placing health as an equal part of the company’s focus (as a part of the newly constructed division, RB Health). The company has a stated focus around improving sales within its chosen powermarkets and is expected to push a strategy of global engagement around its most prominent and broadest-based brands led by the ever-present analgesic Nurofen.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Reckitt Benckiser Plc (RB) in Consumer Health

Euromonitor International's report on Reckitt Benckiser Plc. (RB) delivers a detailed strategic analysis of the company's business, examining its performance in the Vitamins and Dietary Supplements market and the global economy.

Company and market share data provide a detailed look at the financial position of Reckitt Benckiser Plc. (RB), while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of Reckitt Benckiser Plc. (RB).

This report examines:
  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWOT analysis of Reckitt Benckiser Plc. (RB) provides strategic intelligence on:
  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research You Can Trust:

Euromonitor International's company profile reports are written by our Vitamins and Dietary Supplements research team, a dedicated group of analysts that knows the industry inside and out.

Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Delivery format

Reports are delivered in PDF format and can be downloaded from your online account immediately after purchase.


Scope (1)
Scope (2)
Scope (3)

Strategic Evaluation

Key findings
Companies at a glance
Global footprint
Company overview
RB’s consumer health portfolio led by CCAs and analgesics
Sales growth driven by portfolio momentum more than most competitors
RB’s reorganisation will influence company direction in near term

Competitive Positioning

RB’s top competitors overlap most in the global CCAs market
RB strong in W. Europe, US; less so in China, Germany, Japan
Category strength in many countries but some powermarkets need focus
RB brand mix differs sharply between US and rest of world
Greater scrutiny of codeine puts pressure on Nurofen

Category Strategy

RB’s Asian sales lag Western Europe and the US
RB’s brand portfolio skewed by country-level sales differences


Sales prospects for RB

Appendix: Competitor Analytics

Competitor Analytics tool
Market Overlap
Overlap Matrices

Related Reports